| Literature DB >> 35434410 |
Takahiro Sakamoto1,2, Kazuhiko Uchida2, Akihiro Endo1, Hiroyuki Yoshitomi3, Kazuaki Tanabe1.
Abstract
Background: Diffuse gallbladder (GB) wall thickening is caused by elevated systemic venous pressure, such as heart failure (HF). This study investigated the relationship between GB wall thickness (WT) and HF, and the prognostic impact of GBWT. Methods andEntities:
Keywords: Gallbladder wall; Heart failure; Organ congestion; Ultrasonography
Year: 2022 PMID: 35434410 PMCID: PMC8977193 DOI: 10.1253/circrep.CR-21-0155
Source DB: PubMed Journal: Circ Rep ISSN: 2434-0790
Grading Scale for Investigator-Assessed Signs and Symptoms of Congestion
| Signs/symptoms | Scale | |||
|---|---|---|---|---|
| 0 | 1 | 2 | 3 | |
| Dyspnea | None | Seldom | Frequent | Continuous |
| Orthopnea | None | Seldom | Frequent | Continuous |
| Fatigue | None | Seldom | Frequent | Continuous |
| JVD (cmH2O) | ≤6 | 6–9 | 10–15 | ≥15 |
| Rales | None | Bases | <50% | >50% |
| Edema | Absent/trace | Slight | Moderate | Marked |
JVD, jugular venous distention.
Figure 1.Gallbladder wall thickness measured using a sector scan in a patient in the supine position after echocardiography. Measurements of the (A) normal gallbladder wall and (B) diffuse gallbladder wall thickening are noted.
Baseline Characteristics of Participants
| HF | Control | |
|---|---|---|
| 75 [66–84] | 71 [67–71.5] | |
| 55 (64) | 6 (56) | |
| 22 [20–24] | 23 [20–24] | |
| 116 [101–137] | – | |
| 72 [63–79] | – | |
| 56/19/7/4 | – | |
| 0/22/60/4 | ||
| Hypertension | 64 (74) | – |
| Diabetes | 23 (27) | – |
| Dyslipidemia | 40 (47) | – |
| Chronic kidney disease | 43 (50) | – |
| Atrial fibrillation | 32 (37) | – |
| Ischemia | 19 (22) | – |
| Valvular heart disease | 14 (16) | – |
| Cardiomyopathy | 30 (35) | – |
| Hypertension | 12 (14) | – |
| Others | 11 (13) | – |
| ACEI or ARB | 57 (66) | – |
| β-blocker | 50 (58) | – |
| Mineral corticoid receptor antagonists | 30 (35) | – |
| Diuretics | 47 (55) | – |
Unless indicated otherwise, values are presented as the median [interquartile range] or n (%). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HF, heart failure; NYHA, New York Heart Association; SBP, systolic blood pressure.
Laboratory Data, Echocardiography Findings, and Composite Congestion Score in Heart Failure Patients (n=86)
| Hemoglobin (g/dL) | 12 [11–14] |
| Platelet (×103/μL) | 21 [18–25] |
| T-Bil (mg/dL) | 0.7 [0.5–0.9] |
| AST (U/L) | 22 [19–27] |
| ALT (U/L) | 18 [13–26] |
| γ-GTP (U/L) | 26 [18–53.5] |
| ALP (U/L) | 231 [192–293] |
| eGFR (mL/min/1.73 m2) | 45 [29–67] |
| Sodium (mEq/L) | 140 [138–143] |
| BNP (pg/mL) | 182 [77–421] |
| LVEDV (mL) | 76 [59–102] |
| LVSDV (mL) | 32.5 [26–56.75] |
| LVEF (%) | 52 [38–62] |
| LAVI (mL/m2) | 40 [30–52] |
| E/A | 0.8 [0.7–1.3] |
| E/e’ | 12 [9–16] |
| LVOT-VTI (cm) | 17 [13–22] |
| TRPG (mmHg) | 23 [18.5–28.5] |
| Maximum IVC diameter (mm) | 13 [11–16] |
| TAPSE (mm) | 17 [14–20] |
| Pulsed Doppler S wave (cm/s) | 10 [8.5–12] |
| RVFAC (%) | 36 [28–44] |
| MR III/IV | 5 (6) |
| TR III/IV | 11 (13) |
| 0 [0–1] | |
Values are expressed as the median [interquartile range] or n (%). A, late transmitral flow velocity; ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BNP, B-type natriuretic peptide; CCS, composite congestion score; E, early transmitral flow velocity; E/e’, ratio of peak mitral E wave velocity to peak early diastolic myocardial velocity at septal and lateral position recorded using tissue Doppler imaging; eGFR, estimated glomerular filtration rate; γ-GTP, γ-glutamyl transpeptidase; IVC, inferior vena cava; LAVI, left atrial volume index; LVEDV, left ventricular end-diastolic volume; LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction; LVOT-VTI, left ventricular outflow tract-velocity time integral; MR, mitral regurgitation; RVFAC, right ventricular fractional area change; TAPSE, tricuspid annular plane systolic excursion; T-Bil, total bilirubin; TR, tricuspid regurgitation; TRPG, tricuspid regurgitation peak gradient.
Figure 2.Gallbladder (GB) wall thickness in the control and heart failure (HF) groups. The boxes show the interquartile range, with the median value indicated by the horizontal line; whiskers show the range.
Relationship Between Gallbladder Wall Thickness and Clinical Characteristics
| GB wall thickness | ||
|---|---|---|
| R | P value | |
| Hemoglobin | −0.133 | 0.227 |
| Platelet | 0.055 | 0.622 |
| T-Bil | 0.034 | 0.765 |
| AST | −0.029 | 0.799 |
| ALT | 0.054 | 0.626 |
| γ-GTP | 0.162 | 0.144 |
| ALP | 0.325 | 0.004 |
| eGFR | −0.148 | 0.280 |
| Sodium | −0.068 | 0.540 |
| BNP | 0.386 | <0.001 |
| LVEDV | 0.048 | 0.662 |
| LVESV | 0.130 | 0.232 |
| LVEF | −0.192 | 0.077 |
| LAVI | 0.452 | <0.001 |
| E/A | 0.337 | 0.009 |
| E/e’ | 0.179 | 0.128 |
| LVOT-VTI | −0.021 | 0.876 |
| TRPG | 0.280 | 0.013 |
| Maximum IVC diameter | 0.243 | 0.025 |
| TAPSE | −0.311 | 0.006 |
| Pulsed Doppler S wave | −0.308 | 0.008 |
| RVFAC | −0.149 | 0.235 |
| 0.202 | 0.063 | |
Abbreviations as in Table 3.
Figure 3.(A,B) Gallbladder (GB) wall thickness according to heart failure (HF) stage (A) and B-type natriuretic peptide (BNP) tertiles (B). (C) GB wall thickness in patients with no hospitalizations and those with ≥2 hospitalizations in 1 year. The boxes show the interquartile range, with the median value indicated by the horizontal line; whiskers show the range.
Figure 4.Kaplan-Meier plot of event-free (hospitalization for heart failure) survival in patients in high (≥3 mm) and low gallbladder (GB) wall thickness.